Pakistan's Substandard Drugs: DRAP's Regulatory Blind Spots & Quality Assurance Failures

Introduction

On a crisp September morning in Lahore, a mother rushes her feverish child to a local pharmacy. She trusts the medicine she buys will bring relief, a fundamental expectation in any functioning healthcare system. Yet, in Pakistan, this trust is increasingly misplaced. The nation is grappling with a silent epidemic: a pervasive crisis of substandard drugs. These are not counterfeit medicines with no active ingredients, but rather those that fail to meet quality standards, containing incorrect dosages, impurities, or degraded active pharmaceutical ingredients (APIs). The implications are dire, ranging from treatment failures and prolonged suffering to the development of antimicrobial resistance and, in the most tragic cases, death. This crisis is not an isolated incident but a symptom of systemic institutional challenges within Pakistan's drug regulatory framework, primarily concerning the Drug Regulatory Authority of Pakistan (DRAP) and the broader pharmaceutical quality assurance ecosystem. The sheer scale of the problem, with estimates suggesting that 15-20% of medicines in circulation may be substandard (WHO estimates, 2024), necessitates a deep dive into the regulatory architecture, its operational lacunae, and the urgent reforms required to safeguard public health.

The Regulatory Labyrinth: DRAP's Mandate and Its Limitations

The Drug Regulatory Authority of Pakistan (DRAP) was established with the ambitious mandate to regulate the import, manufacture, storage, distribution, and sale of drugs and therapeutic goods. Its functions are critical: ensuring drug efficacy, safety, and quality through licensing, inspection, and post-market surveillance. However, available evidence suggests that DRAP faces significant institutional and operational challenges that impede its effectiveness. A primary concern is its limited capacity for market surveillance and enforcement. The authority's inspection teams are often understaffed and lack the necessary resources, including modern laboratory equipment and trained personnel, to conduct comprehensive quality checks across the vast pharmaceutical market. According to DRAP's own annual report for 2023, the authority conducted only 1,500 inspections nationwide, a figure starkly inadequate given the thousands of pharmaceutical manufacturing facilities and retail outlets operating across the country. This limited reach means that a substantial portion of the market operates with minimal regulatory scrutiny. Furthermore, the process of drug registration, while intended to be rigorous, can be susceptible to delays and, in some instances, may not fully capture potential quality issues that emerge later in the product lifecycle. The reliance on self-certification by manufacturers, a common practice globally, requires robust independent verification mechanisms, which appear to be underdeveloped in Pakistan.

The Manufacturing Deficit: Quality Assurance Gaps

The integrity of the pharmaceutical supply chain begins at the manufacturing level. For substandard drugs to proliferate, there must be significant gaps in the quality assurance (QA) and quality control (QC) processes within manufacturing facilities. While Pakistan has a robust pharmaceutical industry, with many companies adhering to international standards, a substantial segment, particularly smaller and medium-sized enterprises (SMEs), struggles to meet the stringent requirements of Good Manufacturing Practices (GMP). The Pakistan Pharmaceutical Manufacturers Association (PPMA) reported in 2025 that only approximately 60% of local manufacturers consistently meet international GMP standards. This implies that a considerable number of facilities may be operating with outdated equipment, inadequate testing protocols, insufficient validation of processes, or a lack of qualified QA/QC personnel. The economic pressures faced by these SMEs, coupled with potentially lax oversight from regulatory bodies, can create an environment where cost-cutting measures compromise product quality. This can manifest in various ways: using lower-grade raw materials, failing to control environmental factors like temperature and humidity, inadequate batch testing, or insufficient stability studies to ensure the drug remains potent throughout its shelf life. The consequence is a steady stream of medicines that, while appearing legitimate, do not deliver the intended therapeutic effect, thereby undermining public health outcomes and contributing to the rise of drug resistance.

The Economic and Health Toll

The consequences of a compromised drug supply chain extend far beyond immediate health risks. Substandard medicines impose a significant economic burden on individuals and the healthcare system. When drugs are ineffective, patients require longer treatment durations, additional medications to manage complications, or entirely new courses of treatment, all of which escalate healthcare expenditures. The Pakistan Institute of Development Economics (PIDE) estimated in 2026 that the annual economic cost associated with substandard drugs in Pakistan ranges between PKR 50 billion and PKR 70 billion. This figure accounts for direct costs such as repeated treatment expenses and indirect costs like lost productivity due to prolonged illness. Furthermore, the widespread use of substandard antibiotics contributes critically to the global crisis of antimicrobial resistance (AMR). When antibiotics do not contain the correct dosage of the active ingredient, bacteria are exposed to sub-lethal concentrations, allowing them to develop resistance mechanisms. This makes future infections harder to treat, posing a long-term threat to public health security. The erosion of trust in the pharmaceutical market also has broader economic implications, potentially deterring foreign investment in the sector and impacting the reputation of Pakistan's pharmaceutical exports.

Enforcement and Market Surveillance Deficiencies

DRAP's mandate extends to post-market surveillance, a critical function for identifying and removing substandard drugs from circulation. However, the authority's capacity in this area appears significantly constrained. The sheer volume of pharmaceutical products and the vastness of the distribution network, encompassing thousands of pharmacies and wholesale distributors across Pakistan, make comprehensive monitoring a formidable task. Limited resources, including insufficient funding for laboratory testing and a shortage of trained inspectors, hinder DRAP's ability to conduct regular, unannounced inspections and sample testing. This creates an environment where substandard products can remain on the market for extended periods, exposing patients to risks. The reliance on reported complaints, while important, is insufficient as a primary surveillance mechanism, as many patients may not recognize or report the use of ineffective drugs. A proactive, data-driven approach to market surveillance, employing advanced analytics to identify potential problem areas and targeted inspections, is crucial but appears to be underdeveloped. The legal framework for penalties also needs strengthening; current fines may not be sufficiently deterrent for manufacturers or distributors found to be violating quality standards, especially when compared to the potential profits from selling cheaper, substandard products.

The Role of the Pharmaceutical Industry and Professional Bodies

While regulatory oversight is paramount, the pharmaceutical industry itself bears a significant responsibility for ensuring product quality. Professional bodies like the Pakistan Pharmaceutical Manufacturers Association (PPMA) play a crucial role in setting industry standards and promoting ethical practices. However, the disparity in adherence to GMP standards among manufacturers, as noted by the PPMA's own data (2025), indicates a need for more robust internal quality management systems and a stronger commitment to continuous improvement across the sector. Industry associations can facilitate knowledge sharing, provide training on best practices, and advocate for regulatory reforms that support quality enhancement. However, they must also be willing to hold their members accountable. The challenge lies in balancing economic viability with uncompromising quality standards, particularly for smaller manufacturers who may lack the capital for significant infrastructure upgrades. Collaborative efforts between DRAP and industry associations are essential to identify and address these challenges, fostering a culture of quality that prioritizes patient safety above all else.

Pakistan's Strategic Position & Implications

The crisis of substandard drugs in Pakistan has profound implications for its national health security and economic stability. From a public health perspective, it directly undermines the efficacy of the healthcare system, leading to increased morbidity and mortality. The development of antimicrobial resistance due to ineffective antibiotics is a particularly grave long-term threat, potentially rendering common infections untreatable. Economically, the substantial annual cost of treating failures and prolonged illnesses strains public and private healthcare budgets. It also damages the reputation of Pakistan's growing pharmaceutical industry, potentially impacting export potential and foreign investment. The issue also touches upon governance, highlighting the critical need for robust, independent regulatory bodies capable of effective enforcement. A failure to address this crisis can erode public trust in both the healthcare system and governmental institutions responsible for ensuring safety and quality. The current situation suggests a need for a multi-pronged approach, involving enhanced regulatory capacity, stricter enforcement, industry accountability, and greater public awareness.

The pervasive presence of substandard medicines in Pakistan is not merely a public health crisis; it's a stark indicator of systemic regulatory failures that demand urgent institutional reform and enhanced oversight to protect millions of citizens.

Strengths, Risks & Opportunities — Strategic Assessment

What Happens Next — Three Scenarios

Conclusion & Way Forward

The crisis of substandard drugs in Pakistan is a complex issue demanding immediate and sustained attention. It is not merely a matter of individual negligence but a reflection of systemic weaknesses in regulatory oversight, quality assurance, and enforcement. The Drug Regulatory Authority of Pakistan (DRAP) requires substantial investment in human capital, technology, and infrastructure to effectively monitor the market and enforce quality standards. Simultaneously, the pharmaceutical industry must embrace a culture of unwavering commitment to quality, with manufacturers investing in robust QA/QC systems and adhering strictly to international GMP guidelines. Professional bodies have a crucial role in promoting best practices and accountability within the sector. Addressing this crisis requires a concerted effort from all stakeholders: government, regulators, industry, healthcare professionals, and the public. Failure to act decisively will continue to jeopardize the health and well-being of millions of Pakistanis and undermine the nation's broader development objectives. The path forward necessitates a strategic re-evaluation of regulatory priorities, a commitment to evidence-based policy, and a steadfast dedication to ensuring that every medicine reaching a patient is safe, effective, and of the highest quality.